Ascendis Shares Rally Premarket as FDA Doesn't Seek New Studies
By Colin Kellaher
Shares of Ascendis Pharma AS rose sharply in premarket trading Monday after the biopharmaceutical company said the U.S. Food & Drug Administration turned away its application seeking approval of TransCon PTH for adults with hypoparathyroidism but didn't request any new studies.
Hellerup, Denmark-based Ascendis said the FDA issued a complete response letter that raised concerns related to the manufacturing control strategy for variability of delivered dose in the TransCon PTH drug/device combination product.
An FDA complete response letter indicates the agency won't approve an application in its current form.
Ascendis said the FDA didn't express any concerns about the clinical data the company submitted, nor did the agency request any new preclinical studies or Phase 3 trials to evaluate safety or efficacy.
The company early last month has warned that the FDA had identified undisclosed deficiencies with the application, sending shares plummeting.
Ascendis on Monday said it believes it is well prepared to address the FDA's concerns, adding that it will request a "Type A" meeting with the agency to help determine the best path forward.
According to FDA guidelines, Type A meetings are aimed at resolving disputes and helping stalled product-development programs proceed, with scheduling targeted to occur within 30 days of receipt of a written request.
Shares of Ascendis, which closed Friday at $69.96, were recently up 17%, to $81.85, in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 01, 2023 08:01 ET (12:01 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks
-
After Earnings, Is Disney Stock a Buy, a Sell, or Fairly Valued?
-
Home Depot Earnings: Macro Factors Pinch Demand, but Long-Term Outlook Intact
-
Tariffs On Chinese EVs Offer US Automakers a Chance to Capture Demand
-
The Best REITs to Buy
-
3 Hot Stocks to Buy That Still Look Undervalued
-
After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?